PharmaEssentia Corporation
6446
Rankning i aktier
#1443
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Aktiekurs
$36.73
Senast synkroniserad: 2026-10-20
Marknadsvärde
$15.19B
Förändring (1 dag)
-1.70%
Förändring (1 år)
141.45%
Land
TW
Handel PharmaEssentia Corporation (6446)
Kategori
Healthcare
Antal utestående aktier för PharmaEssentia Corporation (6446)
Antal utestående aktier per June 2026: 504.54M
Enligt de senaste finansiella rapporterna och aktiekursen för PharmaEssentia Corporation är det aktuella antalet utestående aktier 504.54M. I slutet av December 2023 hade företaget 357.63M utestående aktier. Antalet utestående aktier påverkas vanligtvis av aktiesplit och återköp av aktier.
Historik över utestående aktier för PharmaEssentia Corporation (6446) från 2010 till 2026
Utestående aktier vid slutet av varje år
| År | Utestående aktier | Ändra |
|---|---|---|
| 2026 (TTM) | 504.54M | 39.70% |
| 2024 | 361.15M | 0.98% |
| 2023 | 357.63M | 13.47% |
| 2022 | 315.19M | 9.24% |
| 2021 | 288.52M | 6.05% |
| 2020 | 272.06M | 11.95% |
| 2019 | 243.02M | -2.49% |
| 2018 | 249.23M | 0.35% |
| 2017 | 248.36M | 6.59% |
| 2016 | 233.00M | 7.71% |
| 2015 | 216.33M | 0.61% |
| 2014 | 215.01M | 7.64% |
| 2013 | 199.75M | 37.81% |
| 2012 | 144.95M | 4.85% |
| 2011 | 138.25M | 0.00% |
| 2010 | 138.25M | 0.00% |
Utestående aktier för liknande företag eller konkurrenter
| Företag | Utestående aktier | Skillnad | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | 375.55% |
IN
|
